Kura Oncology (KURA) announced the first U.S. commercial sale of KOMZIFTI has been completed. Under Kura’s collaboration and license agreement with Kyowa Kirin Co. and Kyowa Kirin Inc., this milestone triggers a $135 million payment from Kyowa Kirin to Kura, which Kura expects to receive prior to year-end. KOMZIFTI was approved by the U.S. Food and Drug Administration on November 13, 2025.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology’s Growth Potential Boosted by KOMZIFTI’s NCCN Inclusion and Competitive Advantages
- Positive Outlook on Kura Oncology: Komzii’s Approval and Safety Profile Drive Buy Rating
- Kura Oncology price target raised to $28 from $11 at Barclays
- FDA Calendar: These Are the Upcoming FDA Drug Approvals
- Kura Oncology price target raised to $30 from $29 at BofA